Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: Systemic review and meta-analysis

Yu Tsung Chen, Che Yuan Hsu, Yu Ning Chien, Woan Ruoh Lee, Yu-Chen Huang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening reactions, mainly to drug, characterized by epidermal necrosis and mucous membrane ulceration. SCORTEN-predicted mortality has been used to assess the efficacy of treatments comparing with actual mortality. Several literatures about cyclosporine have shown its ability to halt disease progression and decrease mortality. Objectives This study was aimed to provide a more evidence-based review by conducting a meta-analysis of cyclosporine for the treatment of SJS/TEN. Methods We conducted a systemic review of articles published before Jan 31, 2017. The outcomes were mortality rate and SCORTEN-based standardized mortality ratio (SMR). The pooled odds ratio (OR) and SMR ratio were analyzed from these extracted data. Results There were 7 observational controlled studies (1 historical controlled study) which met the inclusion criteria. The overall mortality rate for patients receiving cyclosporine was 7.1%. The observed mortality was significantly lower than predicted mortality in patients receiving cyclosporine (pooled SMR: 0.42; 95% CI, 0.19–0.95). The pooled estimate of ORs for 4 studies describing observed mortality in cyclosporine to intravenous immunoglobulins (IVIg) group was 0.40 (95%CI, 0.06–2.69). Comparison of SMR between cyclosporine and IVIg was presented with the pooled SMR ratio, which showed no significant difference in SMR ratio between two treatments (SMR ratio, 0.49, 95% CI, 0.08–2.89). Conclusion We have provided the first meta-analysis study regarding the efficacy on mortality of cyclosporine for treatment of SJS/TEN. From the existing research, cyclosporine has a beneficial effect on mortality. And there is a trend that cyclosporine demonstrated better survival whether in pooled OR or SMR ratio than IVIg. Due to the limitations of current studies, a double-blind randomized controlled trial is still urged.

Original languageEnglish
Pages (from-to)131-137
Number of pages7
JournalDermatologica Sinica
Volume35
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Stevens-Johnson Syndrome
Cyclosporine
Meta-Analysis
Mortality
Intravenous Immunoglobulins
Odds Ratio

Keywords

  • Cyclosporine
  • Meta-analysis
  • Stevens-Johnson syndrome
  • Systemic review
  • Toxic epidermal necrolysis

ASJC Scopus subject areas

  • Dermatology

Cite this

Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis : Systemic review and meta-analysis. / Chen, Yu Tsung; Hsu, Che Yuan; Chien, Yu Ning; Lee, Woan Ruoh; Huang, Yu-Chen.

In: Dermatologica Sinica, Vol. 35, No. 3, 01.09.2017, p. 131-137.

Research output: Contribution to journalArticle

@article{5dc49c1bde384f7ba343cad46c7a4267,
title = "Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: Systemic review and meta-analysis",
abstract = "Background Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening reactions, mainly to drug, characterized by epidermal necrosis and mucous membrane ulceration. SCORTEN-predicted mortality has been used to assess the efficacy of treatments comparing with actual mortality. Several literatures about cyclosporine have shown its ability to halt disease progression and decrease mortality. Objectives This study was aimed to provide a more evidence-based review by conducting a meta-analysis of cyclosporine for the treatment of SJS/TEN. Methods We conducted a systemic review of articles published before Jan 31, 2017. The outcomes were mortality rate and SCORTEN-based standardized mortality ratio (SMR). The pooled odds ratio (OR) and SMR ratio were analyzed from these extracted data. Results There were 7 observational controlled studies (1 historical controlled study) which met the inclusion criteria. The overall mortality rate for patients receiving cyclosporine was 7.1{\%}. The observed mortality was significantly lower than predicted mortality in patients receiving cyclosporine (pooled SMR: 0.42; 95{\%} CI, 0.19–0.95). The pooled estimate of ORs for 4 studies describing observed mortality in cyclosporine to intravenous immunoglobulins (IVIg) group was 0.40 (95{\%}CI, 0.06–2.69). Comparison of SMR between cyclosporine and IVIg was presented with the pooled SMR ratio, which showed no significant difference in SMR ratio between two treatments (SMR ratio, 0.49, 95{\%} CI, 0.08–2.89). Conclusion We have provided the first meta-analysis study regarding the efficacy on mortality of cyclosporine for treatment of SJS/TEN. From the existing research, cyclosporine has a beneficial effect on mortality. And there is a trend that cyclosporine demonstrated better survival whether in pooled OR or SMR ratio than IVIg. Due to the limitations of current studies, a double-blind randomized controlled trial is still urged.",
keywords = "Cyclosporine, Meta-analysis, Stevens-Johnson syndrome, Systemic review, Toxic epidermal necrolysis",
author = "Chen, {Yu Tsung} and Hsu, {Che Yuan} and Chien, {Yu Ning} and Lee, {Woan Ruoh} and Yu-Chen Huang",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.dsi.2017.04.004",
language = "English",
volume = "35",
pages = "131--137",
journal = "Dermatologica Sinica",
issn = "1027-8117",
publisher = "臺灣皮膚科醫學會",
number = "3",

}

TY - JOUR

T1 - Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis

T2 - Systemic review and meta-analysis

AU - Chen, Yu Tsung

AU - Hsu, Che Yuan

AU - Chien, Yu Ning

AU - Lee, Woan Ruoh

AU - Huang, Yu-Chen

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening reactions, mainly to drug, characterized by epidermal necrosis and mucous membrane ulceration. SCORTEN-predicted mortality has been used to assess the efficacy of treatments comparing with actual mortality. Several literatures about cyclosporine have shown its ability to halt disease progression and decrease mortality. Objectives This study was aimed to provide a more evidence-based review by conducting a meta-analysis of cyclosporine for the treatment of SJS/TEN. Methods We conducted a systemic review of articles published before Jan 31, 2017. The outcomes were mortality rate and SCORTEN-based standardized mortality ratio (SMR). The pooled odds ratio (OR) and SMR ratio were analyzed from these extracted data. Results There were 7 observational controlled studies (1 historical controlled study) which met the inclusion criteria. The overall mortality rate for patients receiving cyclosporine was 7.1%. The observed mortality was significantly lower than predicted mortality in patients receiving cyclosporine (pooled SMR: 0.42; 95% CI, 0.19–0.95). The pooled estimate of ORs for 4 studies describing observed mortality in cyclosporine to intravenous immunoglobulins (IVIg) group was 0.40 (95%CI, 0.06–2.69). Comparison of SMR between cyclosporine and IVIg was presented with the pooled SMR ratio, which showed no significant difference in SMR ratio between two treatments (SMR ratio, 0.49, 95% CI, 0.08–2.89). Conclusion We have provided the first meta-analysis study regarding the efficacy on mortality of cyclosporine for treatment of SJS/TEN. From the existing research, cyclosporine has a beneficial effect on mortality. And there is a trend that cyclosporine demonstrated better survival whether in pooled OR or SMR ratio than IVIg. Due to the limitations of current studies, a double-blind randomized controlled trial is still urged.

AB - Background Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening reactions, mainly to drug, characterized by epidermal necrosis and mucous membrane ulceration. SCORTEN-predicted mortality has been used to assess the efficacy of treatments comparing with actual mortality. Several literatures about cyclosporine have shown its ability to halt disease progression and decrease mortality. Objectives This study was aimed to provide a more evidence-based review by conducting a meta-analysis of cyclosporine for the treatment of SJS/TEN. Methods We conducted a systemic review of articles published before Jan 31, 2017. The outcomes were mortality rate and SCORTEN-based standardized mortality ratio (SMR). The pooled odds ratio (OR) and SMR ratio were analyzed from these extracted data. Results There were 7 observational controlled studies (1 historical controlled study) which met the inclusion criteria. The overall mortality rate for patients receiving cyclosporine was 7.1%. The observed mortality was significantly lower than predicted mortality in patients receiving cyclosporine (pooled SMR: 0.42; 95% CI, 0.19–0.95). The pooled estimate of ORs for 4 studies describing observed mortality in cyclosporine to intravenous immunoglobulins (IVIg) group was 0.40 (95%CI, 0.06–2.69). Comparison of SMR between cyclosporine and IVIg was presented with the pooled SMR ratio, which showed no significant difference in SMR ratio between two treatments (SMR ratio, 0.49, 95% CI, 0.08–2.89). Conclusion We have provided the first meta-analysis study regarding the efficacy on mortality of cyclosporine for treatment of SJS/TEN. From the existing research, cyclosporine has a beneficial effect on mortality. And there is a trend that cyclosporine demonstrated better survival whether in pooled OR or SMR ratio than IVIg. Due to the limitations of current studies, a double-blind randomized controlled trial is still urged.

KW - Cyclosporine

KW - Meta-analysis

KW - Stevens-Johnson syndrome

KW - Systemic review

KW - Toxic epidermal necrolysis

UR - http://www.scopus.com/inward/record.url?scp=85022008822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022008822&partnerID=8YFLogxK

U2 - 10.1016/j.dsi.2017.04.004

DO - 10.1016/j.dsi.2017.04.004

M3 - Article

AN - SCOPUS:85022008822

VL - 35

SP - 131

EP - 137

JO - Dermatologica Sinica

JF - Dermatologica Sinica

SN - 1027-8117

IS - 3

ER -